You just read:

Risdiplam Demonstrates Preliminary Evidence of Clinical Benefit in Type 1, 2, & 3 Spinal Muscular Atrophy Patients

News provided by

PTC Therapeutics, Inc.

Oct 03, 2018, 07:30 ET